1Rustin GJ, Quinn M, Thigpen T, et al. Re: New guidelines to evaluate the response to treatment in solid tumors(ovarian cancer)[J]. J Natl Cancer Inst, 2004, 96(6):487-488.
2Vergote I, Rustin GJ, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)gynecologic cancer intergroup [J]. J Natl Cancer Inst, 2000, 92(18): 1534-1535.
3Shapiro JD, Millward Mj, Rischin D, et al. Activity of gemeitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel[J].Gynecol Oncol, 1996, 63(1):89-93.
4Moufarij MA, Phillips DR, Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines[J]. Mol Pharmacol, 2003, 63(4) : 862-869.
5Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: A phase Ⅱ study of the Gynecologic Oncology Group[J]. Gynecol Oncol, 2006, 103(2):446-450.
6Bozas G, Bamias A, Kout Soukou V, et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma [J]. Gynecol Oncol, 2007, 104(3): 580-585.
7Tewari D, Monk B J, Hunter M, et al. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma[J]. Invest New Drugs, 2004, 22(4): 475-480.
8Lehoczky O, Pulay T. Experience with gemcitabine-carboplatin chemotherapy in relapsed ovarian cancer [J]. Orv Hetil, 2006, 147(30): 1405-1408.
9Li L,Cheng FW,Wang F,et al. The activation of TLR7 regulates the expression of VEGF,TIMP1, MMP2, IL-6, andIL-15 in Hela cells [J]. Molecular and Cellular Biochemistry,2014,389(1-2) :43-49.
10Wang S,Fang W. Increased expression of hepatoma-derived growth factor correlates with poor prognosis in human na- sopharyngeal carcinoma [J]. Histopathology, 2011,58 (2) : 217-224.
